Payment overview · 2025
General Payments
$759.81
41 reported records · 8 companies
Healthcare provider profile · identity verified
Bhaskar Sahay, MD
Allopathic & Osteopathic Physicians|General Practice · CLOVIS, NM · NPI 1568405587
Verified facts
What the public records show
CMS Open Payments records show Bhaskar Sahay, MD received $759.81 in general payments during 2025 across 41 reported records.
ABBVIE INC. accounted for 30.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $233.49 | 30.7% | 14 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $227.65 | 30.0% | 14 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $103.33 | 13.6% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $82.67 | 10.9% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.31 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.63 | 4.4% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $19.21 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.52 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $759.81 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $227.65 | 14 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $205.52 | 12 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $103.33 | 5 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $82.67 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.63 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $27.97 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 977 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 886 | 112 |
| Furosemide | Furosemide | 553 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 92 |
| Lisinopril | Lisinopril | 490 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 432 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 75 |
| Gabapentin | Gabapentin | 360 | 75 |
| Potassium Chloride | Potassium Chloride | 351 | 78 |
| Metformin Hcl | Metformin Hcl | 321 | 63 |
| Trazodone Hcl | Trazodone Hcl | 273 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 59 |
| Omeprazole | Omeprazole | 242 | 59 |
| Simvastatin | Simvastatin | 229 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 213 | 64 |
| Losartan Potassium | Losartan Potassium | 201 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 47 |
| Januvia | Sitagliptin Phosphate | 197 | 25 |
| Eliquis | Apixaban | 194 | 33 |
| Donepezil Hcl | Donepezil Hcl | 187 | 20 |
| Montelukast Sodium | Montelukast Sodium | 182 | 30 |
| Sertraline Hcl | Sertraline Hcl | 164 | 40 |
| Metformin Hcl Er | Metformin Hcl | 160 | 35 |
| Allopurinol | Allopurinol | 153 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 50 |
| Azithromycin | Azithromycin | 136 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 25 |
| Carvedilol | Carvedilol | 121 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 29 |
| Tramadol Hcl | Tramadol Hcl | 118 | 32 |
| Clonazepam | Clonazepam | 108 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 100 | 24 |
| Trulicity | Dulaglutide | 93 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 92 | 15 |
| Glipizide | Glipizide | 90 | 18 |
| Mirtazapine | Mirtazapine | 85 | 19 |
| Memantine Hcl | Memantine Hcl | 84 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 83 | 14 |
| Atenolol | Atenolol | 79 | 14 |
| Divalproex Sodium | Divalproex Sodium | 79 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 16 |
| Bupropion Xl | Bupropion Hcl | 76 | 22 |
| Famotidine | Famotidine | 76 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 16 |
| Methylprednisolone | Methylprednisolone | 71 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 20 |
| Spironolactone | Spironolactone | 67 | 11 |
| Prednisone | Prednisone | 66 | 13 |
| Levetiracetam | Levetiracetam | 65 | 13 |
| Ondansetron Odt | Ondansetron | 65 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 21 |
| Cephalexin | Cephalexin | 61 | 16 |
| Farxiga | Dapagliflozin Propanediol | 61 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 40 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 11 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 15 |
| Estradiol | Estradiol | 55 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Novolin R | Insulin Regular, Human | 50 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 36 |
| Lovastatin | Lovastatin | 49 | 11 |
| Lorazepam | Lorazepam | 48 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 25 |
| Naloxone Hcl | Naloxone Hcl | 44 | 44 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 11 |
| Cefdinir | Cefdinir | 36 | 26 |
| Cefuroxime | Cefuroxime Axetil | 36 | 28 |
| Meloxicam | Meloxicam | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 25 |
| Fentanyl | Fentanyl | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Mupirocin | Mupirocin | 29 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 27 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 16 |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Np Thyroid | Thyroid,pork | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Pulmicort Flexhaler | Budesonide | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Mupirocin | Mupirocin Calcium | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $759.81 · 41 records | ABBVIE INC. | ACTHAR, AIRSUPRA, Bimzelx, EVENITY, PURIFIED CORTROPHIN GEL, RINVOQ, SKYRIZI, TREMFYA, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error